Literature DB >> 18591306

Contemporary practice patterns and beliefs regarding tocolysis among u.s. Maternal-fetal medicine specialists.

Nathan S Fox1, Shari E Gelber, Robin B Kalish, Stephen T Chasen.   

Abstract

OBJECTIVE: To estimate maternal-fetal medicine specialists' practice patterns and perceived risks and benefits to tocolysis.
METHODS: We performed a mail-based survey of all Society for Maternal-Fetal Medicine (SMFM) members in the United States. Subjects were asked whether they would recommend tocolysis and what would be their first-line tocolytic in five scenarios: 1) acute preterm labor; 2) maintenance tocolysis after arrested preterm labor; 3) repeat acute preterm labor; 4) preterm premature rupture of membranes (PROM) without contractions; and 5) preterm PROM with contractions.
RESULTS: A total of 827 (46%) SMFM members responded. Ninety-six percent, 56%, 56%, 32%, and 29% would recommend tocolysis for acute preterm labor, repeat acute preterm labor, preterm PROM with contractions, preterm PROM without contractions, and maintenance tocolysis, respectively. The most common first-line tocolytic was magnesium for acute preterm labor (45%) and repeat acute preterm labor (41%); nifedipine was the most common maintenance tocolysis (79%). Eighty percent believed tocolysis was associated with moderate or significant benefit in the setting of acute preterm labor; however, fewer than 50% responded similarly for the other four scenarios. In all five scenarios, more than 50% of respondents indicated there was minimal or no risk associated with tocolysis. Having a nonacademic practice was independently associated with the recommendation for tocolysis.
CONCLUSION: Almost all maternal-fetal medicine specialists recommend tocolysis in the setting of acute preterm labor, and many recommend tocolysis for other indications. Magnesium and nifedipine are the most commonly prescribed first-line tocolytics. LEVEL OF EVIDENCE: III.

Entities:  

Mesh:

Year:  2008        PMID: 18591306     DOI: 10.1097/AOG.0b013e318176158e

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.

Authors:  Ahmed M Nader; Sara K Quinney; Hala M Fadda; David R Foster
Journal:  AAPS J       Date:  2016-04-22       Impact factor: 4.009

2.  Magnesium sulfate tocolysis and intraventricular hemorrhage in very preterm infants.

Authors:  Anna Petrova; Rajeev Mehta
Journal:  Indian J Pediatr       Date:  2011-05-28       Impact factor: 1.967

3.  The effect of antenatal magnesium sulfate on intraventricular hemorrhage in premature infants: a systematic review and meta-analysis.

Authors:  Yousef Moradi; Rozhin Khateri; Ladan Haghighi; Shoaib Dehghani; Shiva Mansouri Hanis; Mehrdad Valipour; Zahra Najmi; Zahra Fathollahy; Meisam Allahmoradi; Kamyar Mansori
Journal:  Obstet Gynecol Sci       Date:  2020-06-24

4.  Prenatal exposure to β2-adrenergic receptor agonists and risk of autism spectrum disorders.

Authors:  Lisa A Croen; Susan L Connors; Marilyn Matevia; Yinge Qian; Craig Newschaffer; Andrew W Zimmerman
Journal:  J Neurodev Disord       Date:  2011-08-27       Impact factor: 4.025

5.  Differences between evidence-based recommendations and actual clinical practice regarding tocolysis: a prospective multicenter registry study.

Authors:  Emina Nazifovic; Heinrich Husslein; Ioana Lakovschek; Florian Heinzl; Elisabeth Wenzel-Schwarz; Philipp Klaritsch; Ekrem Kilic; Sarah Hoesel; Rudolf Bind; Magdalena Pabinger; Harald Zeisler; Lorenz Kuessel
Journal:  BMC Pregnancy Childbirth       Date:  2018-11-16       Impact factor: 3.007

6.  Tocolytic Treatment for the Prevention of Preterm Birth from a Taiwanese Perspective: A Survey of Taiwanese Obstetric Specialists.

Authors:  Howard Hao Lee; Chang-Ching Yeh; Szu-Ting Yang; Chia-Hao Liu; Yi-Jen Chen; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2022-04-01       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.